Oncternal Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oncternal Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013417
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab and TK216. The company’s pipeline compounds are primarily focused on exciting targets which are uniquely expressed within cancer cells. Oncternal addresses different medical challenges from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T). Its Cirmtuzumab is currently in a phase 1 trial for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The company has academic collaborations to identify and develop novel research approaches. Oncternal is headquartered in San Diego, California, the US.

Oncternal Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Merger 20
Oncternal Therapeutics Merges with Tokalas 20
Licensing Agreements 21
Oncternal Therapeutics Enters into Licensing Agreement with University of California 21
Oncternal Therapeutics Inc – Key Competitors 22
Oncternal Therapeutics Inc – Key Employees 23
Oncternal Therapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Product Approvals 25
Jul 13, 2016: TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer 25
Jun 20, 2016: Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma 26
Clinical Trials 27
Aug 30, 2016: Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncternal Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Oncternal Therapeutics Merges with Tokalas 20
Oncternal Therapeutics Enters into Licensing Agreement with University of California 21
Oncternal Therapeutics Inc, Key Competitors 22
Oncternal Therapeutics Inc, Key Employees 23

★海外企業調査レポート[Oncternal Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Honda Motor Co., Ltd.:企業の戦略・SWOT・財務情報
    Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Vision RT Ltd:企業の戦略的SWOT分析
    Vision RT Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Haisco Pharmaceutical Group Co Ltd (002653)-製薬・医療分野:企業M&A・提携分析
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations and bulk drugs. The company's product portfolio comprises injection for trace elements, compound vitamin, invert sugar, fat soluble …
  • QEP Resources, Inc. (QEP):石油・ガス:M&Aディール及び事業提携情報
    Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southern Region essentially in Texas and Louisiana. In Northern Region, the company owns productive w …
  • Occidental Petroleum Corporation:企業の戦略・SWOT・財務分析
    Occidental Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Occidental Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • MedImmune LLC-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibo …
  • Morgan Advanced Materials plc (MGAM):企業の財務・戦略的SWOT分析
    Summary Morgan Advanced Materials Plc (Morgan) is a diversified company. The company designs, manufactures and markets technical ceramics, thermal ceramics, molten metal systems, electrical carbon, braze alloys, fire protection products, seals and bearings, specialty graphite, and composites and def …
  • SATT South East SAS-製薬・医療分野:企業M&A・提携分析
    Summary SATT South East SAS (SATT South East), formerly Satt Paca Corse SAS, a subsidiary of SATT Association is a business and consumer services company that offers technology transfer services. The company offers invention disclosure, intellectual property management, economic market, technology c …
  • Torchlight Energy Resources Inc (TRCH):企業の財務・戦略的SWOT分析
    Summary Torchlight Energy Resources Inc (Torchlight Energy), formerly Known as Pole Perfect Studios Inc, is an oil and gas exploration and production company. The company’s activities include acquisition, exploration and development of domestic oil fields. Its business process includes investment ev …
  • French National Institute of Health and Medical Research:製薬・医療:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Earthstone Energy Inc (ESTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Earthstone Energy Inc (Earthstone Energy), formerly Basic Earth Science Systems Inc is an independent oil and gas company that offers acquisition, exploration, production and development of oil and gas properties. The company's activities include acquiring, drilling, developing and producing …
  • Ingles Markets Inc:企業の戦略・SWOT・財務情報
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Aratana Therapeutics Inc (PETX):製薬・医療:M&Aディール及び事業提携情報
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • NEX Group plc. (IAP):企業の戦略的SWOT分析
    NEX Group plc. (IAP) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Jouve SA:企業の戦略的SWOT分析
    Jouve SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Pudumjee Paper Products Limited:戦略・SWOT・企業財務分析
    Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report Summary Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cineworld Group Plc:企業の戦略・SWOT・財務分析
    Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report Summary Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Packaging Corporation of America (PKG):企業の財務・戦略的SWOT分析
    Packaging Corporation of America (PKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Gannett Co., Inc.:戦略・SWOT・企業財務分析
    Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆